# A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

> **NCT07027345** · PHASE2 · RECRUITING · sponsor: **BioMendics, LLC** · enrollment: 40 (estimated)

## Conditions studied

- Epidermolysis Bullosa Simplex

## Interventions

- **DRUG:** 5% TolaSure Topical Gel
- **DRUG:** Topical Placebo Gel

## Key facts

- **NCT ID:** NCT07027345
- **Lead sponsor:** BioMendics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2025-12
- **Final completion:** 2026-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07027345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07027345, "A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07027345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*